Sei Investments Co. Buys 28,811 Shares of Smith & Nephew SNATS, Inc. $SNN

Sei Investments Co. increased its position in shares of Smith & Nephew SNATS, Inc. (NYSE:SNN) by 29.1% in the 1st quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 127,719 shares of the medical equipment provider’s stock after purchasing an additional 28,811 shares during the quarter. Sei Investments Co.’s holdings in Smith & Nephew SNATS were worth $4,059,000 at the end of the most recent reporting period.

Other large investors have also recently bought and sold shares of the company. Royal Bank of Canada increased its holdings in Smith & Nephew SNATS by 16.7% in the 1st quarter. Royal Bank of Canada now owns 340,428 shares of the medical equipment provider’s stock valued at $9,657,000 after buying an additional 48,784 shares during the period. Goldman Sachs Group Inc. lifted its holdings in shares of Smith & Nephew SNATS by 49.2% during the 1st quarter. Goldman Sachs Group Inc. now owns 1,771,401 shares of the medical equipment provider’s stock worth $50,255,000 after acquiring an additional 583,809 shares during the period. Focus Partners Wealth lifted its holdings in shares of Smith & Nephew SNATS by 59.8% during the 1st quarter. Focus Partners Wealth now owns 19,438 shares of the medical equipment provider’s stock worth $552,000 after acquiring an additional 7,277 shares during the period. Cetera Investment Advisers boosted its position in shares of Smith & Nephew SNATS by 5.9% during the 2nd quarter. Cetera Investment Advisers now owns 17,731 shares of the medical equipment provider’s stock worth $543,000 after acquiring an additional 983 shares in the last quarter. Finally, EverSource Wealth Advisors LLC boosted its position in shares of Smith & Nephew SNATS by 219.2% during the 2nd quarter. EverSource Wealth Advisors LLC now owns 5,261 shares of the medical equipment provider’s stock worth $161,000 after acquiring an additional 3,613 shares in the last quarter. 25.64% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several brokerages have commented on SNN. Canaccord Genuity Group lowered their price objective on shares of Smith & Nephew SNATS from $32.00 to $30.00 and set a “hold” rating for the company in a research report on Monday, May 11th. The Goldman Sachs Group reaffirmed a “buy” rating on shares of Smith & Nephew SNATS in a report on Monday, May 25th. Weiss Ratings downgraded Smith & Nephew SNATS from a “hold (c+)” rating to a “hold (c)” rating in a report on Thursday, June 11th. Barclays lowered Smith & Nephew SNATS from an “equal weight” rating to an “underweight” rating in a research note on Wednesday. Finally, Kepler Capital Markets cut Smith & Nephew SNATS from a “buy” rating to a “hold” rating in a report on Thursday, June 4th. Two research analysts have rated the stock with a Buy rating, six have given a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average price target of $30.93.

Smith & Nephew SNATS Trading Down 1.5%

Shares of NYSE SNN opened at $29.68 on Friday. The company has a 50 day simple moving average of $30.45 and a 200 day simple moving average of $32.14. Smith & Nephew SNATS, Inc. has a 1 year low of $28.56 and a 1 year high of $38.79. The company has a current ratio of 2.14, a quick ratio of 1.25 and a debt-to-equity ratio of 0.62.

Smith & Nephew SNATS Dividend Announcement

The firm also recently declared a dividend, which will be paid on Friday, November 6th. Shareholders of record on Friday, October 2nd will be given a $0.312 dividend. This represents a yield of 205.0%. The ex-dividend date is Friday, October 2nd.

Smith & Nephew SNATS Company Profile

Smith & Nephew plc is a global medical technology company specializing in the design, development and manufacture of advanced surgical devices, orthopaedic reconstruction implants, trauma and extremities products, sports medicine solutions and wound care therapies. Founded in 1856 in Hull, United Kingdom, the company has grown through both organic innovation and strategic acquisitions to offer a broad portfolio that addresses patient needs across joint replacement, minimally invasive surgery and wound healing.

In its orthopaedics business, Smith & Nephew provides hip and knee replacement systems, modular joint revision implants and biologic solutions for bone repair.